No Data
No Data
Lake Street Maintains KORU Medical Systems(KRMD.US) With Buy Rating, Maintains Target Price $4
Craig-Hallum Maintains KORU Medical Systems(KRMD.US) With Buy Rating
KORU Medical Systems Presents Data at Partnership Opportunities in Drug Delivery (PODD) Conference Demonstrating Nursing Preference for Use of KORU FreedomEdge Infusion System Over Manual Syringe Administration for Subcutaneous Oncology Infusion
KORU Medical Systems to Report Third Quarter 2024 Financial Results on November 13, 2024
The Past Five Years for KORU Medical Systems (NASDAQ:KRMD) Investors Has Not Been Profitable
Here's Why We're Not At All Concerned With KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Situation
No Data
No Data